Market Overview

XenoPort May Be Beneficiary of Biogen Patent Filings

Share:
Related BIIB
Biogen Shares Not Too Healthy After Q1 Miss
Morgan Stanley Reviews Biogen Earnings
Biogen Misses On Tecfidera (Investor's Business Daily)
Related XNPT
Catalysts To Watch For In RBC Capital's 2015 Top Small-Cap Biotechs
Jefferies Weighs In On Specialty Pharmaceuticals After Management Meetings, Raises Price Targets On 5 Stocks

Brian Abrahams, a Wells Fargo analyst, believes that Biogen (NASDAQ: BIIB) MS pill patents will be a positive boost for XenoPort (NASDAQ: XNPT).

Further patent applications could provide patent protection until 2032 for Biogen's BG-12, which should benefit XenoPort's '829 drug, an earlier stage derivative of BG-12, with added protection from generic competition.

BIIB is currently up 1.5 percent in pre-market trading, while XNPT is currently unchanged.

Latest Ratings for BIIB

DateFirmActionFromTo
Mar 2015BMO CapitalMaintainsOutperform
Mar 2015CitigroupMaintainsBuy
Mar 2015Stifel NicolausDowngradesBuyHold

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Analyst Ratings

 

Related Articles (BIIB + XNPT)

Around the Web, We're Loving...